Cadre (CDRE) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
14 Jan, 2026Company overview and business model
Manufactures highly engineered safety equipment for professionals, with 80% of 2024 revenue from products and 20% from distribution.
Serves over 23,000 first responders and federal agencies in 104+ countries, with 2,600+ employees and 21 manufacturing facilities.
Focuses on mission-critical products with recurring demand, supported by customer refresh cycles and industry tailwinds.
Implements a leadership-centric operating model emphasizing lean processes, continuous improvement, and innovation.
Core product categories include duty gear, EOD, body armor, and nuclear safety.
Financial performance and outlook
Total revenue grew 55% and adjusted EBITDA grew 97% from FY2020 to FY2025E, with 740 bps margin expansion.
Q3 2025 net sales were $155.9M, up from $109.4M in Q3 2024; gross margin improved to 42.7%.
Adjusted EBITDA for Q3 2025 was $29.8M (19.1% margin), up from $13.5M (12.4%) in Q3 2024.
FY2025 guidance: net sales of $624M–$630M, adjusted EBITDA of $112M–$116M, and capital expenditures of $7M–$8M.
Net leverage at 1.4x as of September 30, 2025, with $150.9M in cash and $311.2M in total debt.
Growth strategy and M&A
Completed six acquisitions since IPO, focusing on strong margins, recurring revenues, and defensible market positions.
Recent acquisitions include TYR Tactical ($93M FY2024 revenue), Alpha Safety, Carr's Engineering, ICOR, Cyalume, and Radar.
M&A strategy targets new markets, category leadership, and increased customer wallet share, with disciplined criteria for financial and market resilience.
Robust acquisition pipeline to accelerate growth and expand product suite and geographic footprint.
Recent deals have provided entry into new verticals, especially in nuclear and tactical safety markets.
Latest events from Cadre
- Strong FY2025 results and disciplined M&A fuel growth, with FY2026 sales guidance up to $758M.CDRE
Investor presentation23 Mar 2026 - Record EBITDA and net income growth in 2025, with double-digit 2026 outlook and higher dividend.CDRE
Q4 202511 Mar 2026 - Nuclear safety and engineered products drive growth, margin expansion, and resilience.CDRE
Investor Day 20253 Feb 2026 - Apex armor and robotics launches showcase innovation and global expansion focus.CDRE
Investor Update1 Feb 2026 - Q2 net sales up 19% to $144.3M, adjusted EBITDA margin 19.6%, 2024 guidance unchanged post-cyber event.CDRE
Q2 20241 Feb 2026 - Stable demand, innovation, and operational focus drive growth and margin expansion.CDRE
Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - Cybersecurity incidents hit Q3, but record backlog and acquisitions support strong outlook.CDRE
Q3 202416 Jan 2026 - Strong market positions and strategic acquisitions drive growth in public safety and nuclear sectors.CDRE
CJS Securities 26th Annual "New Ideas for the New Year” Investor Conference14 Jan 2026 - £75M acquisition doubles global nuclear scale and expands safety, robotics, and medicine reach.CDRE
M&A Announcement10 Jan 2026